Rhythm Pharmaceuticals Inc.'s (RYTM) phase III TRANSCEND trial has met its primary endpoint, and shares are up 4% in premarket trading today.
TRANSCEND is a pivotal phase III trial evaluating the company's marketed drug Setmelanotide, a melanocortin-4 receptor (MC4R) agonist, for the treatment of acquired hypothalamic obesity.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com